Elicio Therapeutics (ELTX) AI Stock Analysis

• Market Cap: $79.77M
• Dividend Yield: N/A
• Average Volume (3M): 42.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: N/A
• EPS Growth: 27.65%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -4.45
• Shares Outstanding: 15,953,524
• 10 Day Avg. Volume: 57,351
• 30 Day Avg. Volume: 42,285
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.00
• Price Target Upside: 120.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Elicio Therapeutics is facing financial instability, with negative revenue growth and high reliance on external funding. Technical indicators signal bearish momentum, and the valuation is unattractive due to ongoing losses. Positive corporate developments present potential strategic improvements, but substantial financial risks remain.

Positive Factors

Clinical Trial Success

Positive results for ELI-002 7P could drive meaningful share price appreciation and might prove sufficient to catalyze partnership.

Potential Revenue

Potential successful commercialization of ELI-002 7P across multiple solid tumor types could yield peak revenues exceeding $550M in the U.S. alone by 2035.

Negative Factors

Clinical Trial Risks

Risks include failure to generate clear proof-of-concept clinical efficacy data showing the impact of ELI-002 7P in KRAS-mutated cancers.

Financial Performance

Elicio Therapeutics reported a net loss of $4.25 per share—wider than previously estimated net loss of $3.62 per share.

Elicio Therapeutics Business Overview & Revenue Model

Company Description

Elicio Therapeutics (ELTX) is a biotechnology company focused on developing innovative immunotherapies to treat cancer and other diseases. The company operates in the biopharmaceutical sector and is dedicated to leveraging its proprietary Amphiphile platform to enhance the potency and durability of immune responses. Elicio's core products include a pipeline of cancer vaccines and immune-modulating therapies designed to target and eliminate cancer cells effectively.

How the Company Makes Money

Elicio Therapeutics makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company generates revenue by partnering with pharmaceutical companies for the co-development and licensing of its technologies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales. Additionally, Elicio may receive funding from grants and research collaborations with academic institutions and government agencies, which contribute to its earnings.

Elicio Therapeutics Financial Statement Overview

Summary

Elicio Therapeutics faces significant financial challenges with no revenue generation, persistent losses, and negative cash flows. The balance sheet shows high leverage risk, and the cash flow statement indicates liquidity challenges and dependency on financing.

Income Statement

Elicio Therapeutics has not generated any revenue in the most recent year, marking a significant decline from past revenue levels. The company has consistently posted negative EBIT and net income, indicating ongoing operational challenges. Margins are negative, reflecting substantial expenses relative to nonexistent revenue. Overall, the income statement suggests financial instability and a lack of profitability.

Balance Sheet

The company's balance sheet shows a positive stockholders' equity in the most recent year, an improvement from previously negative equity. However, the debt-to-equity ratio is high due to significant liabilities, which indicates leverage risk. Total assets are relatively low compared to liabilities, reflecting a weak equity position. Despite improvements, the balance sheet indicates potential financial risk due to leverage.

Cash Flow

Elicio Therapeutics reports negative operating and free cash flow, indicating cash outflows from operations without sufficient inflows. The free cash flow has worsened compared to the previous year, highlighting cash management challenges. Financing activities provided a positive cash influx, suggesting reliance on external funding. Overall, the cash flow statement reflects liquidity challenges and dependency on financing.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	28.31M	2.88M	1.49M
	Gross Profit
-579.00K	-1.17M	-1.06M	27.08M	1.06M	351.00K
	EBIT
-30.66M	-35.74M	-23.73M	-25.47M	-15.72M	-12.34M
	EBITDA
-34.06M	-32.97M	-23.55M	-51.92M	-15.53M	-40.16M
	Net Income Common Stockholders
-35.02M	-35.20M	-28.21M	-26.40M	-15.71M	-12.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.81M	12.89M	6.16M	9.28M	14.97M	6.81M
	Total Assets
0.00	27.15M	22.66M	14.81M	19.66M	8.84M
	Total Debt
0.00	6.92M	7.48M	11.80M	439.43K	867.60K
	Net Debt
6.81M	-5.98M	1.33M	2.52M	-14.53M	-5.94M
	Total Liabilities
0.00	15.77M	124.81M	89.35M	68.80M	43.73M
	Stockholders Equity
6.65M	11.37M	-102.15M	-74.54M	-49.14M	-34.90M
Cash Flow		Free Cash Flow
-29.29M	-32.76M	-22.83M	-24.46M	-16.90M	-9.78M
	Operating Cash Flow
-29.29M	-32.69M	-22.18M	-23.94M	-16.70M	-9.29M
	Investing Cash Flow
3.00K	-32.00K	-653.84K	-525.36K	-199.92K	-489.10K
	Financing Cash Flow
48.78M	38.61M	21.20M	19.39M	25.06M	6.29M

Elicio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Negative. The current price of 5 is below the 20-day moving average (MA) of 6.73, below the 50-day MA of 7.65, and below the 200-day MA of 5.64, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 23.49 is Positive, neither overbought nor oversold. The STOCH value of 6.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTX.

Elicio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.35B	1.18	-46.25%	2.67%	19.35%	1.28%
ADAP	46 Neutral	$56.90M	―	-273.36%	―	194.23%	45.50%
FATE	42 Neutral	$121.48M	―	-54.21%	―	-78.55%	-0.92%
AFMD	42 Neutral	$9.47M	―	-151.46%	―	-95.23%	-325.89%
ALXO	38 Underperform	$26.16M	―	-88.91%	―	―	30.37%
ELTX	29 Underperform	$79.77M	―	-9999.00%	―	―	27.65%
AGEN	26 Underperform	$43.03M	―	260.68%	―	-33.81%	23.02%

Elicio Therapeutics Corporate Events

Elicio Therapeutics Appoints New Chief Strategy and Financial Officer

On March 21, 2025, Elicio Therapeutics appointed Preetam Shah, Ph.D., M.B.A., as Chief Strategy and Financial Officer, effective March 24, 2025. Dr. Shah’s extensive experience in corporate finance and strategy is expected to be a significant asset as Elicio advances its immunotherapy platform and prepares for key clinical milestones. His appointment comes at a crucial time for the company, which is focusing on the development of its lead product candidate, ELI-002, and other cancer vaccines. This strategic leadership change is anticipated to bolster Elicio’s efforts in aligning financial and corporate strategies with its goal of delivering cutting-edge cancer immunotherapeutics.

Elicio Therapeutics Advances with New Clinical Updates

On January 23, 2025, Elicio Therapeutics announced the addition of a corporate presentation on its website, detailing updates on its clinical programs and projected plans. The presentation highlighted ELI-002’s progress, including its potential as a monotherapy for high relapse-risk mKRAS+ cancers, and reported significant T-cell response results from Phase 1 trials. The company also raised $33 million to support its operations into Q2 2025, with several clinical trials planned in the coming years, positioning Elicio to advance its pipeline and reinforce its place in the cancer immunotherapy market.